Microbiome-Focused Food Supplement for Evaporative Dry Eye Due to Meibomian Gland Dysfunction

Incluison criteria: 1. Adults aged 18-65 years. 2. Participants were required to meet all of the following criteria: * Presence of dry eye symptoms, defined as an OSDI-6 summed score ≥4 at baseline. * Objective evidence of tear film homeostasis loss in at least one eye, defined by at least one of the following: A: Non-invasive tear break-up time (NIBUT) \<10 seconds, and/or B: Ocular surface fluorescein staining consistent with DED, defined as: * Corneal and/or conjunctival fluorescein staining graded ≥1 using the Oxford scale, and/or * Lid wiper epitheliopathy graded ≥1 using the Korb grading system 3. Ability to provide written informed consent and comply with study procedures. 4. Willingness to maintain stable use of permitted background measures (e.g., preservative-free artificial tears) and to avoid initiating new probiotics/prebiotics during the trial. Exclusion criteria: 1. Sjögren syndrome or other active systemic autoimmune disease with significant ocular involvement (investigator judgment). 2. Active ocular infection, acute blepharitis flare, or active allergic conjunctivitis requiring escalation of therapy. 3. Ocular surgery (including cataract) or significant ocular trauma within 6 months prior to the Screening Visit. 4. Previous LASIK or any prior corneal surgery at any time. 5. Use of topical cyclosporine, lifitegrast, or topical ocular corticosteroids within 6-8 weeks prior to baseline, or planned initiation during the treatment period. 6. Punctal plugs within 3 months prior to baseline or planned during the study. 7. Use of glaucoma medications or history of glaucoma filtering surgery. 8. Contact lens use within 30 days prior to baseline or planned use during the study. 9. Systemic isotretinoin within 6 months prior to baseline. 10. Systemic antibiotic use within 8 weeks prior to baseline. 11. Eyelid abnormalities affecting lid function (e.g., lagophthalmos, blepharospasm, ectropion, entropion, severe trichiasis). 12. Active thyroid eye disease (thyroid orbitopathy) or clinically significant ocular surface exposure secondary to thyroid dysfunction. 13. Extensive ocular surface scarring or conditions compromising ocular surface integrity, including Stevens-Johnson syndrome, prior chemical burn, recurrent corneal erosions, persistent epithelial defects, or prior severe ocular trauma. 14. Known hypersensitivity to study product ingredients. 15. Any medical or ocular condition that, in the investigator's opinion, would compromise patient safety or study integrity. 16. Pregnancy or breastfeeding (if applicable) or planning pregnancy during the intervention period. 17. Gastrointestinal diseases known to significantly affect digestion, absorption, or intestinal physiology, including but not limited to inflammatory bowel disease, celiac disease, or a history of major gastrointestinal surgery 18. Individuals following restrictive or specialized dietary patterns, including ketogenic, vegan, or similar diets